Clinical trial
Safety Study of Rapamycin Administered Before and During Radiotherapy to Treat…
NCT00409994 · Maastricht Radiation Oncology, Other · Completed
Key facts
| NCT number | NCT00409994 |
|---|---|
| Title | Safety Study of Rapamycin Administered Before and During Radiotherapy to Treat Rectum Cancer |
| Official title | A Clinical Trial Testing Rapamycin, an mTOR-inhibitor, in Combination With Preoperative Radiotherapy in Operable Rectum Cancer: a Phase I and Phase II Study |
| Lead sponsor | Maastricht Radiation Oncology, Other |
| Collaborators | Academisch Ziekenhuis Maastricht |
| Status | Completed |
| Phase | Phase 1/Phase 2 |
| Study type | Interventional |
| Conditions | Rectum Cancer |
| Intervention type | Drug |
| Interventions | Rapamycin |
| Enrollment | 44 |
| Start date | Sep 1, 2006 |
| Primary completion | Aug 3, 2018 |
| Completion | Dec 1, 2018 |
| First posted | Dec 12, 2006 |
| Last update posted | Mar 18, 2019 |
| Countries | Netherlands |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: